ALISON VASQUEZ: Open Payments
NPI 1316621253 · ARLINGTON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,607 in 63 payments from 18 companies in 2025. Trend: 2023 $254 · 2024 $1,325 · 2025 $1,607
Food & beverage: $1,523Education: $84
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 8 | $212 |
| QOL Medical, LLC | 9 | $186 |
| Madrigal Pharmaceuticals | 3 | $184 |
| Regeneron Healthcare Solutions, Inc. | 5 | $158 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $150 |
| Janssen Biotech, Inc. | 3 | $146 |
| GENZYME CORPORATION | 5 | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $117 |
| Phathom Pharmaceuticals, Inc. | 5 | $79 |
| Aimmune Therapeutics, Inc. | 2 | $53 |
Products named: Sucraid, REZDIFFRA, DUPIXENT, VELSIPITY, XIFAXAN, TREMFYA, ENTYVIO, VOQUEZNA.
Industry payments across VA — which companies pay providers there.
